Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

BACKGROUND: Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleeding. We hypothesized that a regimen of rivaroxaban plus a P2Y(12) inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, C. Michael, Pinto, Duane S., Chi, Gerald, Arbetter, Douglas, Yee, Megan, Mehran, Roxana, Bode, Christoph, Halperin, Jonathan, Verheugt, Freek W.A., Wildgoose, Peter, Burton, Paul, van Eickels, Martin, Korjian, Serge, Daaboul, Yazan, Jain, Purva, Lip, Gregory Y.H., Cohen, Marc, Peterson, Eric D., Fox, Keith A.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266420/
https://www.ncbi.nlm.nih.gov/pubmed/27881555
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266420/
https://www.ncbi.nlm.nih.gov/pubmed/27881555
http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025783

Ejemplares similares